ARA-290

$49.99

In stock

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Not for human consumption

Description

ARA-290, also known as cibinetide, is a synthetic peptide derivative of erythropoietin (EPO) designed to selectively target the innate repair receptor (IRR) without activating the erythropoietic pathway. Structurally, it is an 11–amino acid peptide modeled from the B-helix region of EPO, engineered to retain tissue-protective properties while avoiding stimulation of red blood cell production.

In research contexts, ARA-290 is studied for its interaction with the IRR, a heteromeric complex composed of the erythropoietin receptor (EPOR) and the β-common receptor (CD131). This receptor complex has been implicated in cellular signaling pathways related to anti-inflammatory responses, tissue protection, and repair mechanisms.

Due to its targeted receptor activity and short peptide structure, ARA-290 has attracted attention in preclinical and clinical studies exploring metabolic regulation, immune modulation, and neuroprotection.

Size :

10MG

Chemical Formula :

C51H84N16O21

Synonyms :

Cibinetide, PH-BSP, ARA290

Molar Mass :

1257.31

CAS Number :

1208243-50-8

PubChem :

91810664

Total Amount of the Active Ingredient :

160mg (16mg per 1 vial)

Shelf Life :

36 months

ARA-290, also known as cibinetide, is a synthetic peptide derivative of erythropoietin (EPO) designed to selectively target the innate repair receptor (IRR) without activating the erythropoietic pathway. Structurally, it is an 11–amino acid peptide modeled from the B-helix region of EPO, engineered to retain tissue-protective properties while avoiding stimulation of red blood cell production.

In research contexts, ARA-290 is studied for its interaction with the IRR, a heteromeric complex composed of the erythropoietin receptor (EPOR) and the β-common receptor (CD131). This receptor complex has been implicated in cellular signaling pathways related to anti-inflammatory responses, tissue protection, and repair mechanisms.

Due to its targeted receptor activity and short peptide structure, ARA-290 has attracted attention in preclinical and clinical studies exploring metabolic regulation, immune modulation, and neuroprotection.

GET 20% Discount on Your Next 5 Order!

Be the first to know about our new arrivals and once-in-a-lifetime deals.